Cyclacel Pharmaceuticals Ownership 2024 | Who Owns Cyclacel Pharmaceuticals Now?

Overview Forecast RevenueFinancials Chart Transcripts

Institutional Ownership

9.04%

Insider Ownership

4.82%

Retail Ownership

86.14%

Institutional Holders

20.00

Cyclacel Pharmaceuticals Institutional Shareholders

Institutional Shareholders by % of Total Shares

Name	% Total Shares	% Total Assets	Current Shares	Change Amount	Change %	Market Value	Date
WELLS FARGO & COMPANY/MN	-	-	-	-580	-100.00%	-	Dec 31, 2023
NORTHERN TRUST CORP	-	-	-	-14,957	-100.00%	-	Dec 31, 2023
STATE STREET CORP	-	-	-	-10,510	-100.00%	-	Dec 31, 2023
VANGUARD GROUP INC	-	-	-	-86,949	-100.00%	-	Dec 31, 2023
MORGAN STANLEY	-	-	-	-1,200	-100.00%	-	Dec 31, 2023
ACADIAN ASSET MANAGEMENT LLC	-	-	-	-363,367	-100.00%	-	Dec 31, 2023
RENAISSANCE TECHNOLOGIES LLC	-	-	-	-185,500	-100.00%	-	Dec 31, 2023
TWO SIGMA INVESTMENTS, LP	-	-	-	-16,424	-100.00%	-	Dec 31, 2023
GEODE CAPITAL MANAGEMENT, LLC	-	-	-	-86,425	-100.00%	-	Dec 31, 2023
MILLENNIUM MANAGEMENT LLC	-	-	-	-28,759	-100.00%	-	Dec 31, 2023
BLACKROCK INC.	-	-	-	-4,697	-100.00%	-	Dec 31, 2023
CITADEL ADVISORS LLC	-	-	-	-30,745	-100.00%	-	Dec 31, 2023
SIGNATUREFD, LLC	-	-	-	-300	-100.00%	-	Dec 31, 2023
RAYMOND JAMES FINANCIAL SERVICES ADVISORS, INC.	-	-	-	-20,806	-100.00%	-	Dec 31, 2023
TOWER RESEARCH CAPITAL LLC (TRC)	-	-	-	-3,591	-100.00%	-	Dec 31, 2023
POINT72 ASSET MANAGEMENT, L.P.	-	-	-	-230,000	-100.00%	-	Dec 31, 2023
SCHONFELD STRATEGIC ADVISORS LLC	-	-	-	-28,400	-100.00%	-	Dec 31, 2023
ADVISOR GROUP HOLDINGS, INC.	-	-	-	-9,150	-100.00%	-	Dec 31, 2023
MCILRATH & ECK, LLC	-	-	-	-12,500	-100.00%	-	Dec 31, 2023
QUBE RESEARCH & TECHNOLOGIES LTD	-	-	-	-50	-100.00%	-	Dec 31, 2023

Cyclacel Pharmaceuticals's largest institutional shareholder is WELLS FARGO & COMPANY/MN, holding 0.00% of the company's total share outstanding, currently valued at -. The top 10 institutional shareholders own together 0.00% of the company.

Institutional Shareholders by % of Total Assets

Name	% Total Shares	% Total Assets	Current Shares	Change Amount	Change %	Market Value	Date
WELLS FARGO & COMPANY/MN	-	-	-	-580	-100.00%	-	Dec 31, 2023
NORTHERN TRUST CORP	-	-	-	-14,957	-100.00%	-	Dec 31, 2023
STATE STREET CORP	-	-	-	-10,510	-100.00%	-	Dec 31, 2023
VANGUARD GROUP INC	-	-	-	-86,949	-100.00%	-	Dec 31, 2023
MORGAN STANLEY	-	-	-	-1,200	-100.00%	-	Dec 31, 2023
ACADIAN ASSET MANAGEMENT LLC	-	-	-	-363,367	-100.00%	-	Dec 31, 2023
RENAISSANCE TECHNOLOGIES LLC	-	-	-	-185,500	-100.00%	-	Dec 31, 2023
TWO SIGMA INVESTMENTS, LP	-	-	-	-16,424	-100.00%	-	Dec 31, 2023
GEODE CAPITAL MANAGEMENT, LLC	-	-	-	-86,425	-100.00%	-	Dec 31, 2023
MILLENNIUM MANAGEMENT LLC	-	-	-	-28,759	-100.00%	-	Dec 31, 2023
BLACKROCK INC.	-	-	-	-4,697	-100.00%	-	Dec 31, 2023
CITADEL ADVISORS LLC	-	-	-	-30,745	-100.00%	-	Dec 31, 2023
SIGNATUREFD, LLC	-	-	-	-300	-100.00%	-	Dec 31, 2023
RAYMOND JAMES FINANCIAL SERVICES ADVISORS, INC.	-	-	-	-20,806	-100.00%	-	Dec 31, 2023
TOWER RESEARCH CAPITAL LLC (TRC)	-	-	-	-3,591	-100.00%	-	Dec 31, 2023
POINT72 ASSET MANAGEMENT, L.P.	-	-	-	-230,000	-100.00%	-	Dec 31, 2023
SCHONFELD STRATEGIC ADVISORS LLC	-	-	-	-28,400	-100.00%	-	Dec 31, 2023
ADVISOR GROUP HOLDINGS, INC.	-	-	-	-9,150	-100.00%	-	Dec 31, 2023
MCILRATH & ECK, LLC	-	-	-	-12,500	-100.00%	-	Dec 31, 2023
QUBE RESEARCH & TECHNOLOGIES LTD	-	-	-	-50	-100.00%	-	Dec 31, 2023

The largest Cyclacel Pharmaceuticals shareholder by % of total assets is WELLS FARGO & COMPANY/MN. The company owns 0.00 shares of Cyclacel Pharmaceuticals (CYCC), representing 0.00% of its total assets.

Institutional Buyers

Name	% Total Shares	% Total Assets	Current Shares	Change Amount	Change %	Market Value	Date
QUBE RESEARCH & TECHNOLOGIES LTD	-	-	-	-50	-100.00%	-	Dec 31, 2023
SIGNATUREFD, LLC	-	-	-	-300	-100.00%	-	Dec 31, 2023
WELLS FARGO & COMPANY/MN	-	-	-	-580	-100.00%	-	Dec 31, 2023
MORGAN STANLEY	-	-	-	-1,200	-100.00%	-	Dec 31, 2023
TOWER RESEARCH CAPITAL LLC (TRC)	-	-	-	-3,591	-100.00%	-	Dec 31, 2023
BLACKROCK INC.	-	-	-	-4,697	-100.00%	-	Dec 31, 2023
ADVISOR GROUP HOLDINGS, INC.	-	-	-	-9,150	-100.00%	-	Dec 31, 2023
STATE STREET CORP	-	-	-	-10,510	-100.00%	-	Dec 31, 2023
MCILRATH & ECK, LLC	-	-	-	-12,500	-100.00%	-	Dec 31, 2023
NORTHERN TRUST CORP	-	-	-	-14,957	-100.00%	-	Dec 31, 2023
TWO SIGMA INVESTMENTS, LP	-	-	-	-16,424	-100.00%	-	Dec 31, 2023
RAYMOND JAMES FINANCIAL SERVICES ADVISORS, INC.	-	-	-	-20,806	-100.00%	-	Dec 31, 2023
SCHONFELD STRATEGIC ADVISORS LLC	-	-	-	-28,400	-100.00%	-	Dec 31, 2023
MILLENNIUM MANAGEMENT LLC	-	-	-	-28,759	-100.00%	-	Dec 31, 2023
CITADEL ADVISORS LLC	-	-	-	-30,745	-100.00%	-	Dec 31, 2023
GEODE CAPITAL MANAGEMENT, LLC	-	-	-	-86,425	-100.00%	-	Dec 31, 2023
VANGUARD GROUP INC	-	-	-	-86,949	-100.00%	-	Dec 31, 2023
RENAISSANCE TECHNOLOGIES LLC	-	-	-	-185,500	-100.00%	-	Dec 31, 2023
POINT72 ASSET MANAGEMENT, L.P.	-	-	-	-230,000	-100.00%	-	Dec 31, 2023
ACADIAN ASSET MANAGEMENT LLC	-	-	-	-363,367	-100.00%	-	Dec 31, 2023

As of Dec 31 2023, Cyclacel Pharmaceuticals's largest institutional buyer is QUBE RESEARCH & TECHNOLOGIES LTD. The company purchased -50.00 stocks of CYCC, valued at -.

Institutional Sellers

Name	% Total Shares	% Total Assets	Current Shares	Change Amount	Change %	Market Value	Date
ACADIAN ASSET MANAGEMENT LLC	-	-	-	-363,367	-100.00%	-	Dec 31, 2023
POINT72 ASSET MANAGEMENT, L.P.	-	-	-	-230,000	-100.00%	-	Dec 31, 2023
RENAISSANCE TECHNOLOGIES LLC	-	-	-	-185,500	-100.00%	-	Dec 31, 2023
VANGUARD GROUP INC	-	-	-	-86,949	-100.00%	-	Dec 31, 2023
GEODE CAPITAL MANAGEMENT, LLC	-	-	-	-86,425	-100.00%	-	Dec 31, 2023
CITADEL ADVISORS LLC	-	-	-	-30,745	-100.00%	-	Dec 31, 2023
MILLENNIUM MANAGEMENT LLC	-	-	-	-28,759	-100.00%	-	Dec 31, 2023
SCHONFELD STRATEGIC ADVISORS LLC	-	-	-	-28,400	-100.00%	-	Dec 31, 2023
RAYMOND JAMES FINANCIAL SERVICES ADVISORS, INC.	-	-	-	-20,806	-100.00%	-	Dec 31, 2023
TWO SIGMA INVESTMENTS, LP	-	-	-	-16,424	-100.00%	-	Dec 31, 2023
NORTHERN TRUST CORP	-	-	-	-14,957	-100.00%	-	Dec 31, 2023
MCILRATH & ECK, LLC	-	-	-	-12,500	-100.00%	-	Dec 31, 2023
STATE STREET CORP	-	-	-	-10,510	-100.00%	-	Dec 31, 2023
ADVISOR GROUP HOLDINGS, INC.	-	-	-	-9,150	-100.00%	-	Dec 31, 2023
BLACKROCK INC.	-	-	-	-4,697	-100.00%	-	Dec 31, 2023
TOWER RESEARCH CAPITAL LLC (TRC)	-	-	-	-3,591	-100.00%	-	Dec 31, 2023
MORGAN STANLEY	-	-	-	-1,200	-100.00%	-	Dec 31, 2023
WELLS FARGO & COMPANY/MN	-	-	-	-580	-100.00%	-	Dec 31, 2023
SIGNATUREFD, LLC	-	-	-	-300	-100.00%	-	Dec 31, 2023
QUBE RESEARCH & TECHNOLOGIES LTD	-	-	-	-50	-100.00%	-	Dec 31, 2023

As of Dec 31 2023, Cyclacel Pharmaceuticals's biggest institutional seller is ACADIAN ASSET MANAGEMENT LLC. The company sold -0.36M shares of CYCC, valued at -.

Institutional New positions

Name	% Total Shares	% Total Assets	Current Shares	Change Amount	Change %	Market Value	Date

Institutional Sold Out

Name	% Total Shares	% Total Assets	Current Shares	Change Amount	Change %	Market Value	Date
ACADIAN ASSET MANAGEMENT LLC	-	-	-	-363,367	-100.00%	-	Dec 31, 2023
POINT72 ASSET MANAGEMENT, L.P.	-	-	-	-230,000	-100.00%	-	Dec 31, 2023
RENAISSANCE TECHNOLOGIES LLC	-	-	-	-185,500	-100.00%	-	Dec 31, 2023
VANGUARD GROUP INC	-	-	-	-86,949	-100.00%	-	Dec 31, 2023
GEODE CAPITAL MANAGEMENT, LLC	-	-	-	-86,425	-100.00%	-	Dec 31, 2023
CITADEL ADVISORS LLC	-	-	-	-30,745	-100.00%	-	Dec 31, 2023
MILLENNIUM MANAGEMENT LLC	-	-	-	-28,759	-100.00%	-	Dec 31, 2023
SCHONFELD STRATEGIC ADVISORS LLC	-	-	-	-28,400	-100.00%	-	Dec 31, 2023
RAYMOND JAMES FINANCIAL SERVICES ADVISORS, INC.	-	-	-	-20,806	-100.00%	-	Dec 31, 2023
TWO SIGMA INVESTMENTS, LP	-	-	-	-16,424	-100.00%	-	Dec 31, 2023
NORTHERN TRUST CORP	-	-	-	-14,957	-100.00%	-	Dec 31, 2023
MCILRATH & ECK, LLC	-	-	-	-12,500	-100.00%	-	Dec 31, 2023
STATE STREET CORP	-	-	-	-10,510	-100.00%	-	Dec 31, 2023
ADVISOR GROUP HOLDINGS, INC.	-	-	-	-9,150	-100.00%	-	Dec 31, 2023
BLACKROCK INC.	-	-	-	-4,697	-100.00%	-	Dec 31, 2023
TOWER RESEARCH CAPITAL LLC (TRC)	-	-	-	-3,591	-100.00%	-	Dec 31, 2023
MORGAN STANLEY	-	-	-	-1,200	-100.00%	-	Dec 31, 2023
WELLS FARGO & COMPANY/MN	-	-	-	-580	-100.00%	-	Dec 31, 2023
SIGNATUREFD, LLC	-	-	-	-300	-100.00%	-	Dec 31, 2023
QUBE RESEARCH & TECHNOLOGIES LTD	-	-	-	-50	-100.00%	-	Dec 31, 2023

Cyclacel Pharmaceuticals's largest sold out institutional shareholder by shares sold is ACADIAN ASSET MANAGEMENT LLC, sold -0.36M shares, valued at -, as of undefined.

Cyclacel Pharmaceuticals Mutual Fund Holders

Name	% Total Assets	Total Shares	Change Amount	Change %	Date
BRIDGEWAY FUNDS INC	0.03%	64,068	-	-	Mar 28, 2024
Vericimetry Funds	0.02%	2,140	-	-	Mar 31, 2024
FIDELITY CONCORD STREET TRUST	0.00%	83,510	-	-	Feb 29, 2024
VANGUARD INSTITUTIONAL INDEX FUNDS	0.00%	11,507	-	-	Mar 31, 2024
VANGUARD INDEX FUNDS	0.00%	86,949	-	-	Mar 31, 2024
Dimensional ETF Trust	0.00%	12,283	-	-	Jan 31, 2024
FIDELITY CONCORD STREET TRUST	0.00%	5,564	5,564	-	Feb 29, 2024
DFA INVESTMENT DIMENSIONS GROUP INC	0.00%	22,730	-	-	Jan 31, 2024
VANGUARD INDEX FUNDS	0.00%	5,796	-5,796	-50.00%	Mar 31, 2024
Blackstone Alternative Investment Funds	0.00%	600	-	-	Mar 31, 2023
USAA MUTUAL FUNDS TRUST	0.00%	1,340	-	-	Jan 31, 2024
EQ ADVISORS TRUST	0.00%	1,924	-	-	Mar 31, 2024
iSHARES TRUST	0.00%	4,308	-	-	Mar 31, 2024

Cyclacel Pharmaceuticals's largest mutual fund holder by % of total assets is "BRIDGEWAY FUNDS INC", owning 64.07K shares, compromising 0.03% of its total assets.

Cyclacel Pharmaceuticals Institutional Ownership Trends

Institutional Holdings Trend

Date	Holdings	Change %
30 Sep, 23	20	-13.04%
30 Jun, 23	23	-11.54%
31 Mar, 23	26	-13.33%
31 Dec, 22	30	15.38%
30 Sep, 22	26	13.04%
30 Jun, 22	23	-8.00%
31 Mar, 22	25	-16.67%
31 Dec, 21	30	-3.23%
30 Sep, 21	31	14.81%
30 Jun, 21	27	-6.90%
31 Mar, 21	29	107.14%
31 Dec, 20	14	133.33%
30 Sep, 20	6	-25.00%
30 Jun, 20	8	-

As of 30 Sep 23, 20 institutions are holding Cyclacel Pharmaceuticals's shares, representing a decrease of -13.04% compared to the previous quarter.

Shares Outstanding Trend

Date	Shares Outstanding	Change %
30 Sep, 23	1,134,910	-45.03%
30 Jun, 23	2,064,450	-17.83%
31 Mar, 23	2,512,518	2.28%
31 Dec, 22	2,456,591	5.48%
30 Sep, 22	2,328,975	10.51%
30 Jun, 22	2,107,427	-36.47%
31 Mar, 22	3,317,431	2.47%
31 Dec, 21	3,237,568	-12.24%
30 Sep, 21	3,689,082	-9.64%
30 Jun, 21	4,082,476	1.30%
31 Mar, 21	4,029,907	145.74%
31 Dec, 20	1,639,880	703.29%
30 Sep, 20	204,145	-38.48%
30 Jun, 20	331,824	-

Cyclacel Pharmaceuticals (CYCC) has 1.13M shares outstanding as of 30 Sep 23, down -45.03% compared to the previous quarter.

Institutional Ownership Trend

Date	Ownership %	Change %
30 Sep, 23	9.04%	3.34%
30 Jun, 23	16.46%	4.10%
31 Mar, 23	20.04%	4.21%
31 Dec, 22	21.83%	6.10%
30 Sep, 22	18.91%	4.37%
30 Jun, 22	20.79%	1.89%
31 Mar, 22	33.20%	2.78%
31 Dec, 21	34.56%	2.23%
30 Sep, 21	39.38%	2.01%
30 Jun, 21	44.21%	1.37%
31 Mar, 21	56.77%	2.79%
31 Dec, 20	45.13%	256.22%
30 Sep, 20	4.20%	5.65%
30 Jun, 20	8.62%	-

As of 30 Sep 23, Cyclacel Pharmaceuticals is held by 9.04% institutional shareholders, representing a 3.34% growth compared to 30 Jun 23.

Institutional Increased Positions Trend

Date	Increased Positions	Change %
30 Sep, 23	6	20.00%
30 Jun, 23	5	-16.67%
31 Mar, 23	6	-57.14%
31 Dec, 22	14	-22.22%
30 Sep, 22	18	38.46%
30 Jun, 22	13	30.00%
31 Mar, 22	10	-9.09%
31 Dec, 21	11	-21.43%
30 Sep, 21	14	7.69%
30 Jun, 21	13	-45.83%
31 Mar, 21	24	100.00%
31 Dec, 20	12	200.00%
30 Sep, 20	4	-50.00%
30 Jun, 20	8	-

6 institutional shareholders have increased their position in CYCC stock as of 30 Sep 23 compared to 5 in the previous quarter (a 20.00% increase).

Institutional Reduced Positions Trend

Date	Reduced Positions	Change %
30 Sep, 23	5	-
30 Jun, 23	5	-28.57%
31 Mar, 23	7	-
31 Dec, 22	7	75.00%
30 Sep, 22	4	-
30 Jun, 22	4	-42.86%
31 Mar, 22	7	-
31 Dec, 21	7	-22.22%
30 Sep, 21	9	-18.18%
30 Jun, 21	11	175.00%
31 Mar, 21	4	-
31 Dec, 20	-	-100.00%
30 Sep, 20	1	-
30 Jun, 20	-	-

5 institutional shareholders have reduced their position in CYCC stock as of 30 Sep 23 compared to 5 in the previous quarter (a 0.00% increase).

All Institutional Ownership Trend Data

Date	Holdings	Change %	Shares Outstanding	Change %	Ownership %	Change %	Increased Positions	Change %	Reduced Positions	Change %
30 Sep, 23	20	-13.04%	1,134,910	-45.03%	9.04%	3.34%	6	20.00%	5	-
30 Jun, 23	23	-11.54%	2,064,450	-17.83%	16.46%	4.10%	5	-16.67%	5	-28.57%
31 Mar, 23	26	-13.33%	2,512,518	2.28%	20.04%	4.21%	6	-57.14%	7	-
31 Dec, 22	30	15.38%	2,456,591	5.48%	21.83%	6.10%	14	-22.22%	7	75.00%
30 Sep, 22	26	13.04%	2,328,975	10.51%	18.91%	4.37%	18	38.46%	4	-
30 Jun, 22	23	-8.00%	2,107,427	-36.47%	20.79%	1.89%	13	30.00%	4	-42.86%
31 Mar, 22	25	-16.67%	3,317,431	2.47%	33.20%	2.78%	10	-9.09%	7	-
31 Dec, 21	30	-3.23%	3,237,568	-12.24%	34.56%	2.23%	11	-21.43%	7	-22.22%
30 Sep, 21	31	14.81%	3,689,082	-9.64%	39.38%	2.01%	14	7.69%	9	-18.18%
30 Jun, 21	27	-6.90%	4,082,476	1.30%	44.21%	1.37%	13	-45.83%	11	175.00%
31 Mar, 21	29	107.14%	4,029,907	145.74%	56.77%	2.79%	24	100.00%	4	-
31 Dec, 20	14	133.33%	1,639,880	703.29%	45.13%	256.22%	12	200.00%	-	-100.00%
30 Sep, 20	6	-25.00%	204,145	-38.48%	4.20%	5.65%	4	-50.00%	1	-
30 Jun, 20	8	-	331,824	-	8.62%	-	8	-	-	-

Cyclacel Pharmaceuticals Insider Shareholders Trades

Open Market Insider Trades

Date	Name	Relation	Role	Transaction	Buy/Sell	Shares	Price	Value	Shares Held
Dec 26, 2023	McBarron Paul	director, officer	See Remarks	P-Purchase	Buy	1,886	$3.31	$6.25K	33,378
Dec 26, 2023	McBarron Paul	director, officer	See Remarks	P-Purchase	Buy	1,886	$3.19	$6.02K	1,886
Dec 26, 2023	Rombotis Spiro George	director, officer	President and CEO	P-Purchase	Buy	6,070	$3.31	$20.12K	68,658
Dec 26, 2023	Rombotis Spiro George	director, officer	President and CEO	P-Purchase	Buy	6,070	$3.19	$19.36K	6,070

Open Market Insider Buys

Date	Name	Relation	Role	Transaction	Buy/Sell	Shares	Price	Value	Shares Held
Dec 26, 2023	McBarron Paul	director, officer	See Remarks	P-Purchase	Buy	1,886	$3.31	$6.25K	33,378
Dec 26, 2023	McBarron Paul	director, officer	See Remarks	P-Purchase	Buy	1,886	$3.19	$6.02K	1,886
Dec 26, 2023	Rombotis Spiro George	director, officer	President and CEO	P-Purchase	Buy	6,070	$3.31	$20.12K	68,658
Dec 26, 2023	Rombotis Spiro George	director, officer	President and CEO	P-Purchase	Buy	6,070	$3.19	$19.36K	6,070

Insider Sells

Date	Name	Relation	Role	Transaction	Buy/Sell	Shares	Price	Value	Shares Held	Source

All Insider Owners Trades

Date	Name	Relation	Role	Transaction	Buy/Sell	Shares	Price	Value	Shares Held
Jan 31, 2024	SCHWARTZ BRIAN	director, officer	Interim Chief Medical Officer	A-Award	Buy	12,500	-	-	15,205
Jan 31, 2024	SCHWARTZ BRIAN	director, officer	Interim Chief Medical Officer	A-Award	Buy	12,500	$2.28	$28.50K	12,500
Dec 26, 2023	McBarron Paul	director, officer	See Remarks	P-Purchase	Buy	1,886	$3.31	$6.25K	33,378
Dec 26, 2023	McBarron Paul	director, officer	See Remarks	P-Purchase	Buy	1,886	$3.19	$6.02K	1,886
Dec 26, 2023	Rombotis Spiro George	director, officer	President and CEO	P-Purchase	Buy	6,070	$3.31	$20.12K	68,658
Dec 26, 2023	Rombotis Spiro George	director, officer	President and CEO	P-Purchase	Buy	6,070	$3.19	$19.36K	6,070
Jul 03, 2023	Rombotis Spiro George	director, officer	President and CEO	A-Award	Buy	110,000	$0.59	$64.80K	110,000
Jul 03, 2023	BARKER SAM L	director	-	A-Award	Buy	42,438	$0.59	$25.00K	42,438
Jul 03, 2023	BARKER SAM L	director	-	A-Award	Buy	21,219	-	-	40,415
Jul 03, 2023	Spiegel Robert J.	director	-	A-Award	Buy	42,438	$0.59	$25.00K	42,438
Jul 03, 2023	Spiegel Robert J.	director	-	A-Award	Buy	21,219	-	-	39,415
Jul 03, 2023	McBarron Paul	director, officer	See Remarks	A-Award	Buy	70,200	$0.59	$41.35K	70,200
Jul 03, 2023	Kirschbaum Mark	officer	Chief Medical Officer	A-Award	Buy	70,200	$0.59	$41.35K	70,200
Jul 03, 2023	Walker Karin L	director	-	A-Award	Buy	42,438	$0.59	$25.00K	42,438
Jul 03, 2023	Walker Karin L	director	-	A-Award	Buy	21,219	-	-	40,602
Jul 03, 2023	Ferguson Kenneth M.	director	-	A-Award	Buy	21,219	-	-	44,952
Jul 03, 2023	Ferguson Kenneth M.	director	-	A-Award	Buy	42,438	$0.59	$25.00K	42,438
Jul 03, 2023	HENNEY CHRISTOPHER S	director	-	A-Award	Buy	42,438	$0.59	$25.00K	42,438
Jul 03, 2023	HENNEY CHRISTOPHER S	director	-	A-Award	Buy	21,219	-	-	39,415
Jul 03, 2023	SCHWARTZ BRIAN	director	-	A-Award	Buy	42,438	$0.59	$25.00K	42,438

The last insider buy of CYCC was made by McBarron Paul on Dec 26 2023, buying 1,886 shares at $3.31 per share (worth $6.25K).

Cyclacel Pharmaceuticals Insider Ownership Trends

All Insider Trades Trend

Date	Buy	Sell	Buy/Sell Ratio
Q1 2024	2	-	-
Q4 2023	8	-	-
Q2 2023	30	-	-
Q1 2023	6	-	-
Q2 2022	9	-	-
Q4 2021	5	1	500.00%
Q3 2021	1	-	-
Q2 2021	14	-	-
Q4 2020	5	-	-
Q2 2020	7	-	-
Q4 2019	6	-	-
Q2 2019	7	-	-
Q1 2019	9	-	-
Q3 2018	1	-	-
Q2 2018	6	-	-
Q3 2017	2	-	-
Q2 2017	6	-	-
Q1 2017	1	-	-
Q2 2016	7	-	-
Q4 2015	3	-	-

2 total buy trades, and 0 total sell trades (buy/sell ratio of 0%) were made by Cyclacel Pharmaceuticals's insiders, as of Q1 2024.

Open Market Insider Trades Trend

Date	Buy	Sell	Buy/Sell Ratio
Q1 2024	-	-	-
Q4 2023	8	-	-
Q2 2023	-	-	-
Q1 2023	-	-	-
Q2 2022	-	-	-
Q4 2021	1	1	100.00%
Q3 2021	1	-	-
Q2 2021	-	-	-
Q4 2020	-	-	-
Q2 2020	-	-	-
Q4 2019	-	-	-
Q2 2019	-	-	-
Q1 2019	-	-	-
Q3 2018	-	-	-
Q2 2018	-	-	-
Q3 2017	2	-	-
Q2 2017	-	-	-
Q1 2017	1	-	-
Q2 2016	-	-	-
Q4 2015	-	-	-

As of Q1 2024, Insider owners conducted 0 open market buy trades and 0 open market sell trades of Cyclacel Pharmaceuticals's stocks.

Cyclacel Pharmaceuticals Peer Ownership

Ticker	Company
CYT	Cyteir Therapeutics, Inc.
PULM	Pulmatrix, Inc.
NXTC	NextCure, Inc.
IKNA	Ikena Oncology, Inc.
EWTX	Edgewise Therapeutics, Inc.
CTMX	CytomX Therapeutics, Inc.
SPRO	Spero Therapeutics, Inc.
AKTX	Akari Therapeutics, Plc
CNTB	Connect Biopharma Holdings Limited
ASMB	Assembly Biosciences, Inc.
RZLT	Rezolute, Inc.
TPST	Tempest Therapeutics, Inc.
MBRX	Moleculin Biotech, Inc.
OVID	Ovid Therapeutics Inc.
PTIX	Protagenic Therapeutics, Inc.
NLTX	Neurogene Inc.
CBIO	Gyre Therapeutics, Inc.
ELYM	Eliem Therapeutics, Inc.

CYCC Ownership FAQ

Who Owns Cyclacel Pharmaceuticals?

Cyclacel Pharmaceuticals is owned by institutional shareholders (9.04%), insiders (4.82%), and public (86.14%). The largest institutional shareholder of Cyclacel Pharmaceuticals is WELLS FARGO & COMPANY/MN (0% of total shares) and the top mutual fund owner is BRIDGEWAY FUNDS INC (0.03% of total shares).

Who are the major institutional shareholders of Cyclacel Pharmaceuticals?

Cyclacel Pharmaceuticals's major institutional shareholders are WELLS FARGO & COMPANY/MN, NORTHERN TRUST CORP, STATE STREET CORP, VANGUARD GROUP INC, and MORGAN STANLEY. The top five shareholders own together 0% of the company's share outstanding.

How many Cyclacel Pharmaceuticals shareholders are there?

As of Sep 2023, there are 20 institutional shareholders of Cyclacel Pharmaceuticals.

What percentage of Cyclacel Pharmaceuticals is owned by WELLS FARGO & COMPANY/MN?

WELLS FARGO & COMPANY/MN owns 0 shares of Cyclacel Pharmaceuticals, representing 0% of the company's total shares outstanding, valued at $0 (as of Dec 2023).

What percentage of Cyclacel Pharmaceuticals is owned by NORTHERN TRUST CORP?

As of Dec 2023, NORTHERN TRUST CORP holds 0 shares of Cyclacel Pharmaceuticals (CYCC), compromising 0% of the company, valued at $0.

What percentage of Cyclacel Pharmaceuticals is owned by STATE STREET CORP?

STATE STREET CORP is the third largest holder of Cyclacel Pharmaceuticals. The company owns 0 of the company's shares outstanding (worth $0).